Gastric Cancer Harboring an ERBB3 Mutation Treated with a Pyrotinib–Irinotecan Combo: A Case Study

Abstract

Gastric cancer is common, especially in East Asian countries, and is associated with high recurrence and mortality rates. Currently, there is no standard third-line treatment for metastatic gastric cancer. In this report, we present the case of a 69-year-old man with advanced gastric cancer, whose tumor was negative for human epidermal growth factor receptor 2 (HER2) according to immunohistochemical analysis. Next-generation sequencing performed on paraffin sections of the postoperative tumor samples indicated the presence of the ERBB3 V104L mutation. The patient received irinotecan plus pyrotinib as a third-line therapy and achieved a progression-free survival of 7.6 months with a high quality of life. Therefore, the combined administration of irinotecan and pyrotinib may improve the clinical condition of patients with gastric cancer harboring an ERBB3 mutation. Moreover, ERBB3 could be a potential therapeutic target for gastric cancer.

HER2-positive breast cancer progresses rapidly after pyrotinib resistance: acquired RET gene fusion and TP53 gene mutation are potential reasons

“…Pyrotinib is one of the representatives of TKIs. Pyrotinib has been clinically reported to be effective in patients with metastatic breast cancer after failed trastuzumab or pertuzumab treatment [15][16][17][18]. In phase II clinical study (NCT02422199) of Chinese patients with HER2-positive relapsed or metastatic breast cancer, who previously received chemotherapy or trastuzumab was not given, the objective response rates of 'pyrotinib + capecitabine' and 'lapatinib + capecitabine' were 78.5% and 57.1%, respectively, and the progression-free survival was 18.1 months and 7.0 months, respectively [19].…”

Case Report: Significant Efficacy of Pyrotinib in the Treatment of Extensive Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Cutaneous Metastases: A Report of Five Cases

“…There is evidence that HER2 targeting TKIs can enhance the ADCC response and thus act in synergy with anti-HER2 mAbs in the treatment of BC (16,17). There have been clinical reports about the therapeutic effect of pyrotinib in patients with metastatic breast cancer (MBC) who have failed trastuzumab and pertuzumab treatment (18)(19)(20)(21)(22)(23), and pyrotinib has also been found to have a good therapeutic effect on other types of HER2-positive advanced malignancies (24)(25)(26)(27)(28)(29)(30).…”